Stability testing services and drug master file maintenance for antibody drug conjugate adct-701
Active Purchase Order Awarded
- Contract number
- 75N91025P00462
- Awardee
-
ADC Therapeutics America, Inc. UEI Y9MBZX2C5RU5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $194,000
Award facts
- Contract value 100% obligated
- $194,000.00 Current and potential, with all options
- Completion date 46% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- New Providence, NJ 07974, USA
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price purchase order awarded by the National Cancer Institute, a civilian federal agency, to ADC Therapeutics America, Inc. for $194,000.00. The contract is for stability testing services and drug master file maintenance for an antibody drug conjugate, ADCT-701. The contract has an ultimate completion date of December 29, 2027 and was awarded on September 29, 2025. There is no set-aside designation for this contract.
Quick answers
Who was awarded contract 75N91025P00462?
75N91025P00462 was awarded to ADC Therapeutics America, Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2025.
How much is contract 75N91025P00462 worth?
The government has obligated $194,000 on 75N91025P00462.
Was contract 75N91025P00462 competed?
The extent of competition for 75N91025P00462 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award